• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

GSK Makes Post-Brexit Investment in UK


July 27, 2016

GSK has announced £275 million ($360m) of new investments at three of its manufacturing sites in the UK. The news comes as a business confidence booster for the country following its Brexit vote last month.

The new investment will be made across three UK sites:

Barnard Castle in County Durham, one of GSK’s biggest secondary manufacturing sites, employing 1,100 people. 

Montrose in Angus, Scotland, which manufactures active ingredients for respiratory, HIV and vaccine products and employs over 450 staff. 

Ware (Hertfordshire), which employs 1200 staff manufacturing innovative respiratory products.

GSK chief Andrew Witty said: "It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here."


Related Videos